JP2005529152A5 - - Google Patents

Download PDF

Info

Publication number
JP2005529152A5
JP2005529152A5 JP2004505078A JP2004505078A JP2005529152A5 JP 2005529152 A5 JP2005529152 A5 JP 2005529152A5 JP 2004505078 A JP2004505078 A JP 2004505078A JP 2004505078 A JP2004505078 A JP 2004505078A JP 2005529152 A5 JP2005529152 A5 JP 2005529152A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
composition according
dose
antibody
administered
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2004505078A
Other languages
Japanese (ja)
Other versions
JP2005529152A (en
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2003/015874 external-priority patent/WO2003097082A2/en
Publication of JP2005529152A publication Critical patent/JP2005529152A/en
Publication of JP2005529152A5 publication Critical patent/JP2005529152A5/ja
Pending legal-status Critical Current

Links

Claims (13)

クローン病を患うヒト患者の治療用の、少なくとも４mg／kgの投与量で使用される、インターフェロンγに対する抗体を含む医薬組成物であって、当該抗体は、インターフェロンγを中和し、かつ、配列番号１を含むＶL 領域と配列番号２を含むＶH 領域を含む抗体と同一のエピトープに、少なくとも１０8Ｍ-1のアフィニティーで、結合する、前記医薬組成物。 A pharmaceutical composition comprising an antibody against interferon gamma used at a dose of at least 4 mg / kg for the treatment of a human patient suffering from Crohn's disease, said antibody neutralizing interferon gamma and having a sequence The pharmaceutical composition, which binds to the same epitope as an antibody comprising a V L region comprising No. 1 and a V H region comprising SEQ ID No. 2 with an affinity of at least 10 8 M −1 . 前記投与量は４〜１０mg／kgである、請求項１に記載の医薬組成物。   The pharmaceutical composition according to claim 1, wherein the dose is 4 to 10 mg / kg. 前記抗体はヒト化抗体である、請求項１に記載の医薬組成物。   The pharmaceutical composition according to claim 1, wherein the antibody is a humanized antibody. 前記ヒト化抗体はＨｕＺＡＦである、請求項３に記載の医薬組成物。   4. The pharmaceutical composition according to claim 3, wherein the humanized antibody is HuZAF. 前記抗体は、少なくとも１０9Ｍ-1のヒト・インターフェロンγについての結合アフィニティーをもつ、請求項１に記載の医薬組成物。 2. The pharmaceutical composition of claim 1, wherein the antibody has a binding affinity for human interferon gamma of at least 10 9 M −1 . 前記患者に静脈内、筋肉中、又は皮下投与される、請求項１に記載の医薬組成物。   The pharmaceutical composition according to claim 1, wherein the composition is administered intravenously, intramuscularly or subcutaneously to the patient. 前記投与量は、約３０分間〜約６０分間の期間にわたり単一静脈内輸注として投与される、請求項１に記載の医薬組成物。   2. The pharmaceutical composition of claim 1, wherein the dosage is administered as a single intravenous infusion over a period of about 30 minutes to about 60 minutes. 前記投与量は、毎月、６週毎、又は２〜３月後に投与される、請求項１に記載の医薬組成物。   The pharmaceutical composition according to claim 1, wherein the dose is administered every month, every 6 weeks, or after 2 to 3 months. 前記投与後約２８日目に、前記抗体の４〜１０mg／体重１kgの第２投与量を投与する際に使用するための、請求項１に記載の医薬組成物。   The pharmaceutical composition according to claim 1, for use in administering a second dose of 4-10 mg / kg body weight of the antibody about 28 days after the administration. 前記第２投与の量は、前記第１投与量の約５０％である、請求項１に記載の医薬組成物。   The pharmaceutical composition according to claim 1, wherein the amount of the second dose is about 50% of the first dose. 前記第２投与量は、皮下注射を通じて投与される、請求項１０に記載の医薬組成物。   The pharmaceutical composition according to claim 10, wherein the second dose is administered through subcutaneous injection. 前記第１投与量と第２投与量の投与は、少なくとも１００ポイント、前記ヒト患者のＣＤＡＩスコアを低下させる、請求項１に記載の医薬組成物。   The pharmaceutical composition according to claim 1, wherein the administration of the first dose and the second dose reduces the CDAI score of the human patient by at least 100 points. 各々４〜１０mg／kgの２つの投与量から成る一連の処置を投与する際に使用するための、かつ、当該使用により、前記ヒト患者のＣＤＡＩスコアが少なくとも１００ポイント、低減される、請求項１に記載の医薬組成物。   2. For use in administering a series of treatments each consisting of two doses of 4-10 mg / kg, and said use reduces the CDAI score of said human patient by at least 100 points. A pharmaceutical composition according to 1.
JP2004505078A 2002-05-17 2003-05-16 Treatment of Crohn's disease or psoriasis using anti-interferon gamma antibodies Pending JP2005529152A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US15074202A 2002-05-17 2002-05-17
US38331002P 2002-05-22 2002-05-22
PCT/US2003/015874 WO2003097082A2 (en) 2002-05-17 2003-05-16 Treatment of crohn's disease or psoriasis using anti-inteferon gamma antibodies

Publications (2)

Publication Number Publication Date
JP2005529152A JP2005529152A (en) 2005-09-29
JP2005529152A5 true JP2005529152A5 (en) 2006-07-06

Family

ID=29552737

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2004505078A Pending JP2005529152A (en) 2002-05-17 2003-05-16 Treatment of Crohn's disease or psoriasis using anti-interferon gamma antibodies

Country Status (5)

Country Link
EP (1) EP1506002A4 (en)
JP (1) JP2005529152A (en)
AU (1) AU2003231802A1 (en)
CA (1) CA2486147A1 (en)
WO (1) WO2003097082A2 (en)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE173630T1 (en) 1992-12-29 1998-12-15 Genentech Inc TREATMENT OF INFLAMMATORY BOWEL DISEASE WITH INTERFERON-GAMMA INHIBITORS
BRPI0607238B8 (en) * 2005-01-27 2021-05-25 Novimmune Sa anti-human gamma interferon antibodies, uses thereof in the preparation of drugs and pharmaceutical compositions
CN101426514A (en) * 2006-04-25 2009-05-06 英特塞尔股份公司 HCV vaccines
EP2274333A4 (en) * 2008-03-18 2011-06-15 Abbott Lab Methods for treating psoriasis
KR20140097336A (en) 2011-11-23 2014-08-06 암젠 인크 Methods of treatment using an antibody against interferon gamma
MA41271A (en) * 2014-12-26 2017-10-31 Celgene Alpine Invest Company Ii Llc METHODS OF USE OF OLIGONUCLEOTIDES ANTISENS TARGETING SMAD7
US11091543B2 (en) 2015-05-07 2021-08-17 Swedish Orphan Biovitrum Ag Methods, compositions and dosing regimens for treating or preventing interferon-gamma related indications
CA2985001A1 (en) 2015-05-07 2016-11-10 Novimmune Sa Methods and compositions for diagnosis and treatment of disorders in patients with elevated levels of cxcl9 and other biomarkers

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
AU633698B2 (en) 1990-01-12 1993-02-04 Amgen Fremont Inc. Generation of xenogeneic antibodies
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
EP0746609A4 (en) 1991-12-17 1997-12-17 Genpharm Int Transgenic non-human animals capable of producing heterologous antibodies
ATE173630T1 (en) * 1992-12-29 1998-12-15 Genentech Inc TREATMENT OF INFLAMMATORY BOWEL DISEASE WITH INTERFERON-GAMMA INHIBITORS
CA2297692A1 (en) * 1997-08-18 1999-02-25 Innogenetics N.V. Interferon-gamma-binding molecules for treating septic shock, cachexia, immune diseases and skin disorders
US6329511B1 (en) 1998-12-01 2001-12-11 Protein Design Labs, Inc. Humanized antibodies to γ-interferon
US20050019323A1 (en) * 2002-05-22 2005-01-27 Protein Design Labs, Inc. Treatment of Crohn's disease or psoriasis using anti-interferon gamma antibodies

Similar Documents

Publication Publication Date Title
JP2019196370A5 (en)
JP2015187125A5 (en)
HRP20170056T2 (en) Low frequency glatiramer acetate therapy
JP2016074740A5 (en)
JP2016514132A5 (en)
JP2014114288A5 (en)
JP2013533858A5 (en)
RU2019125748A (en) NEW INDICATIONS FOR USE IN TREATMENT WITH ANTIBODIES AGAINST IL-1-BETA
JP2020002172A5 (en)
JP2016516016A5 (en)
JP2007515469A5 (en)
JP2018532715A5 (en)
JP2017537105A5 (en)
KR101900520B1 (en) A combination composition
JP2018531938A5 (en)
FI3356386T3 (en) Method of treating melanocortin-4 receptor pathway-associated disorders
JP2015172060A5 (en)
RU2016149316A (en) TREATMENT OF RHEUMATOID ARTHRITIS
IL299376A (en) Pertuzuniab plus trastuzumab fixed dose combination
JP2019521156A5 (en)
JP2005506345A5 (en)
AU647463B2 (en) A method and a pharmaceutical preparation for treating pain
JP2006508039A5 (en)
JP2021004249A5 (en)
JP2005529152A5 (en)